|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
14
|
|
pubmed:dateCreated |
2003-6-25
|
|
pubmed:abstractText |
Potent 5-HT1A/SSRIs at low nanomolar and subnanomolar concentrations were identified in a series of 1-(1H-indol-4-yloxy)-3-(4-benzo[b]thiophen-2-ylpiperidinyl)propan-2-ols. Incorporation of an alpha-Me group in the piperidine ring with its specific stereochemistry enhanced binding affinity at the 5-HT reuptake site and in vitro 5-HT(1A) antagonist functional activity.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0960-894X
|
|
pubmed:author |
pubmed-author:AhmadLaura JLJ,
pubmed-author:AtkinsonSteven TST,
pubmed-author:HertelLarry WLW,
pubmed-author:HonigschmidtNicholas ANA,
pubmed-author:KochDaniel JDJ,
pubmed-author:KohnTodd JTJ,
pubmed-author:NelsonDavid LDL,
pubmed-author:RoccoVincent PVP,
pubmed-author:ShawJaniceJ,
pubmed-author:SpinazzePatrick GPG,
pubmed-author:TakeuchiKumikoK,
pubmed-author:ThrelkeldPenny GPG,
pubmed-author:WainscottD BradleyDB,
pubmed-author:WongDavid TDT
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
21
|
|
pubmed:volume |
13
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2393-7
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:12824042-Guanosine 5'-O-(3-Thiotriphosphate),
pubmed-meshheading:12824042-Indicators and Reagents,
pubmed-meshheading:12824042-Paroxetine,
pubmed-meshheading:12824042-Piperidines,
pubmed-meshheading:12824042-Propanols,
pubmed-meshheading:12824042-Receptor, Serotonin, 5-HT1A,
pubmed-meshheading:12824042-Serotonin Antagonists,
pubmed-meshheading:12824042-Serotonin Uptake Inhibitors,
pubmed-meshheading:12824042-Stereoisomerism,
pubmed-meshheading:12824042-Structure-Activity Relationship
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Advances Toward new antidepressants beyond SSRIs: 1-aryloxy-3-piperidinylpropan-2-ols with dual 5-HT(1A) receptor antagonism/SSRI activities. Part 2.
|
|
pubmed:affiliation |
Lilly Research Laboratories, A Division of Eli Lilly and Company, IN 46285, Indianapolis, USA. ktak@lilly.com
|
|
pubmed:publicationType |
Journal Article,
Comparative Study
|
